Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

235P - Resumption of menses (ROM), Fertility status perception and pregnancy desire in young breast cancer survivors: A real-world data survey

Date

04 May 2022

Session

Poster Display session

Topics

Tumour Site

Breast Cancer

Presenters

Kevin Salas Espinoza

Citation

Annals of Oncology (2022) 33 (suppl_3): S232-S237. 10.1016/annonc/annonc896

Authors

K.J. Salas Espinoza1, K.M. Roque Perez2, Z.D. Morante Cruz2, G. Valencia Mesias2, P.E. Rioja viera2, H.A. Fuentes2, S.P. Neciosup Delgado2, J.M.M. Cotrina Concha2, H.L. Gomez Moreno2

Author affiliations

  • 1 Universidad Peruana Cayetano Heredia-North Campus, Lima/PE
  • 2 INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima/PE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 235P

Background

The time to resumption of menses (ROM) after long-term treatment for breast cancer is rarely known. Additionally, fertility perception is an important issue to measured quality of life in breast cancer young (BCY) patients. Herein, we describe the incidence of ROM and fertility perception in a developing country.

Methods

We studied medical records from pre-menopausal with breast cancer with or without hormone receptors (HR) diagnosed at the Instituto Nacional de Enfermedades Neoplásicas (INEN) in Lima, Peru from 2010 to 2012. ROM was defined as at least three consecutive menstrual cycles. A 3-question survey about desire to have children and perception about fertility treatment were conducted. Patients were classified according to HR status: in HR-negative ROM was measured at the end of chemotherapy treatment, and for HR-positive patients ROM was evaluated after chemo followed by tamoxifen for 24 months.

Results

From 677 patients, 10.7% (n=73) agreed to complete the survey. Median age was 41 years old (25-45), 15% (n=11) were stage I; 52% (n=38) stage II and 33% (n=24) stage III. HR (+) /HER2 (-) was the most frequent subtype with 59.1% (n=43). Approximately 30% patients (n=25) used chemical blockade (LHRH agonists) and 84% of those patients had undergone oophorectomy. With a median follow-up of 10 years, 24.3% (n=18) had ROM. The median age was 39 years (26-45) and the mean time of ROM was 3.78 months (1-6). In patients ≤ 39 years, 30% (n=9) had ROM and for the patients > 39 years 20% (n=9) had ROM. Only 1 patient was pregnant. The most frequent cause of avoiding birth desire was lack of information (90%). The perception of fertility and access to fertility preservation methods was evaluated in a survey; 19% (n=14) still desired pregnancy and 4% (n=3) thought about undergoing a fertility treatment.

Conclusions

A quarter of the patients with breast cancer have ROM; however, it was higher in younger patients. Despite of the pregnancy desire, the lack of information and access to fertilization techniques make it difficult. These results give us the opportunity to improve multidisciplinary management and include fertility preservation in the discussion.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.